Coronary Artery Bypass Grafts Market Size, Share, Growth, and Industry Analysis, By Type (Off-pump CABG,On-pump CABG,MI direct CABG), By Application (Hospitals,Ambulatory surgical centers (ASCs)), Regional Insights and Forecast to 2035

Coronary Artery Bypass Grafts Market Overview

The global Coronary Artery Bypass Grafts Market in terms of revenue was estimated to be worth USD 19690.43 Million in 2026 and is poised to reach USD 33265.7 Million by 2035, growing at a CAGR of 6% from 2026 to 2035.

The global Coronary Artery Bypass Grafts Market is expanding rapidly due to a sharp rise in cardiovascular diseases, which currently account for 31.4% of global deaths annually. In 2025, over 1.13 million CABG procedures are expected globally, with vein grafts accounting for 68.2% and arterial grafts representing 31.8% of procedures. Technological advancements in minimally invasive techniques have improved surgical success rates by 26.7%. Endoscopic vessel harvesting is used in 59.3% of cases, significantly reducing postoperative complications. Robotic-assisted CABG procedures rose by 38.5% between 2022 and 2025. The demand for coronary artery bypass grafts is rising in both developed and emerging economies.

The USA accounts for 29.6% of the global Coronary Artery Bypass Grafts Market share. In 2025, over 336,000 CABG procedures are projected to take place across the country. Approximately 87.2% of U.S. procedures are performed in hospitals with dedicated cardiac centers. Saphenous vein grafts are used in 71.4% of surgeries, while internal thoracic artery grafts are employed in 61.8%. Robotic-assisted CABG grew by 44.9% from 2022 to 2025 in the U.S. region. Medicare and private insurance cover nearly 91.3% of CABG procedures performed nationwide. Hospital readmission rates following CABG dropped by 12.6% due to innovations in post-op care.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: Increasing prevalence of coronary artery disease drives 61.3% of total CABG demand globally.
• Major Market Restraint: High cost of surgical procedures impacts 47.9% of patient accessibility in low-income regions.
• Emerging Trends: Robotic-assisted CABG adoption has increased by 38.5% since 2022, especially in developed healthcare systems.
• Regional Leadership: North America holds 35.7% of the global Coronary Artery Bypass Grafts Market share.
• Competitive Landscape: Top five manufacturers collectively control 53.2% of global coronary artery bypass graft distribution.
• Market Segmentation: Off-pump CABG represents 41.4%, on-pump CABG 48.7%, and minimally invasive CABG 9.9% of total procedures.
• Recent Development: Endoscopic harvesting systems are used in 59.3% of surgeries worldwide, rising from 48.5% in 2021.

Coronary Artery Bypass Grafts Market Latest Trends

The Coronary Artery Bypass Grafts Market Trends indicate major advancements in both surgical techniques and graft materials. Arterial grafts now account for 31.8% of procedures globally due to improved patency rates. Internal thoracic artery graft usage rose by 23.4% over three years. Endoscopic vessel harvesting is applied in 59.3% of procedures to reduce infection risk and improve healing time. Synthetic graft materials, although still underutilized, represent 6.2% of grafts used in specific re-do procedures. Intraoperative blood flow measurement technologies have seen a 42.1% increase in adoption among cardiovascular surgeons. Hybrid coronary revascularization procedures, combining PCI and CABG, rose by 18.7% in the past year. Outpatient surgical recovery programs led to a 15.6% decrease in hospital stays. Digital preoperative planning tools are now used by 33.4% of cardiac surgery departments to streamline graft sizing and positioning.

Coronary Artery Bypass Grafts Market Dynamics

DRIVER

"Rise in coronary artery disease prevalence."

The increasing rate of cardiovascular conditions such as coronary artery disease is driving market demand, with 197.4 million people globally diagnosed with heart conditions in 2025. Approximately 1.13 million CABG surgeries are performed annually to address severe blockages. Risk factors including hypertension (affecting 42.9% of adults) and diabetes (affecting 10.5%) have led to a 31.6% growth in surgical interventions in high-risk groups. Elderly patients aged 65+ account for 62.7% of CABG procedures. Clinical trials reported that 88.3% of multi-vessel disease patients benefit more from CABG than from PCI, reinforcing the procedure’s preference in advanced cases.

RESTRAINT

"Limited access to advanced surgical facilities."

Globally, 42.3% of hospitals lack access to specialized cardiovascular surgical infrastructure. In low-income regions, CABG procedures are performed in less than 18.7% of cardiac cases. The cost of CABG equipment and post-operative care is cited as a barrier by 47.9% of hospitals. Surgeon shortages affect 34.8% of rural healthcare centers globally. Insurance coverage disparities limit access in 26.4% of global markets. Emerging economies struggle to procure state-of-the-art surgical robots, with adoption rates below 6.3%. These infrastructural and cost limitations slow Coronary Artery Bypass Grafts Market Growth in price-sensitive regions.

OPPORTUNITY

"Rise in demand for minimally invasive and robotic-assisted CABG."

Minimally invasive CABG accounted for 9.9% of global procedures in 2025, a sharp rise from 5.3% in 2020. Robotic-assisted surgeries now make up 12.7% of CABG volume in the U.S., supported by hospital investment in automation. Smaller incision sizes and faster recovery led to a 19.6% reduction in post-operative complications. Medical robotics in cardiac surgery received over 621 new installations globally in 2024. Shorter ICU stays for robotic CABG patients decreased healthcare costs by 14.3%. B2B buyers are focusing on integrating AI-based intraoperative imaging systems that are used in 16.4% of advanced cardiac centers.

CHALLENGE

"Complexity of multi-vessel bypass surgeries."

Multi-vessel CABG procedures represent 68.1% of all CABG surgeries performed in 2025. These surgeries require an average of 3.1 grafts per patient. Surgical durations exceed 4 hours in 57.8% of complex cases. The complication rate is higher in multi-vessel procedures, with 11.4% requiring reoperation or extended ICU care. High intraoperative blood loss was reported in 9.6% of surgeries despite improvements in grafting techniques. Skill dependency is high—only 29.2% of cardiac surgeons worldwide are trained in advanced grafting for triple-vessel disease. Managing these complexities limits the widespread adoption of coronary artery bypass grafts in underserved markets.

Coronary Artery Bypass Grafts Market Segmentation

The Coronary Artery Bypass Grafts Market is segmented based on procedure type and application, enabling suppliers and manufacturers to target specific clinical demands and procurement channels.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Off-pump CABG: Off-pump CABG represented 41.4% of procedures in 2025, offering reduced stroke risk and faster recovery. Surgeons used stabilizers in 83.5% of off-pump cases. Hospitals with hybrid operating rooms showed 28.6% more adoption of this method. Intraoperative complications dropped by 17.8% when off-pump CABG was used for high-risk patients.

The Off-pump CABG segment is projected to grow from USD 6,222.99 million in 2025 to USD 10,079.53 million by 2034, contributing 31.14% market share and registering a CAGR of 5.73%, driven by reduced surgical complications and shorter recovery.

Top 5 Major Dominant Countries in the Off-pump CABG Segment

• United States: The U.S. will reach USD 2,349.87 million by 2034, accounting for 23.31% market share and growing at a CAGR of 5.61%, supported by increasing adoption of beating-heart surgery techniques.
• Germany: Germany will grow to USD 1,348.19 million by 2034, representing 13.37% share and a CAGR of 5.53%, backed by high-volume cardiovascular surgical centers.
• Japan: Japan is expected to achieve USD 1,074.23 million by 2034, holding 10.65% share and a CAGR of 5.64%, with widespread integration of advanced stabilizers.
• China: China will record USD 1,021.44 million by 2034, securing 10.13% share and a CAGR of 5.86%, driven by increasing procedural volume in tertiary hospitals.
• France: France will hit USD 938.07 million by 2034, maintaining a 9.3% share with a CAGR of 5.49%, due to a strong shift toward minimally invasive heart surgery.

On-pump CABG: On-pump CABG remains the dominant procedure type at 48.7% share in 2025. Over 55.2% of triple-vessel disease patients undergo on-pump procedures due to better visibility and control. Cardiopulmonary bypass was used in 93.4% of these surgeries. The average operative time for on-pump CABG is 224 minutes globally.

The On-pump CABG segment is expected to expand from USD 9,854.30 million in 2025 to USD 16,859.82 million by 2034, holding 53.72% of market share and growing at a CAGR of 6.12%, due to better outcomes in complex multi-vessel cases.

Top 5 Major Dominant Countries in the On-pump CABG Segment

• United States: The U.S. will record USD 3,753.13 million by 2034, claiming 22.26% share and CAGR of 6.03%, supported by widespread use in triple-vessel disease treatment.
• China: China is projected at USD 2,471.06 million by 2034, securing 14.66% share and a CAGR of 6.28%, led by increased cardiac hospital infrastructure.
• Germany: Germany will achieve USD 2,093.49 million by 2034, with a 12.42% share and CAGR of 6.08%, owing to advanced cardiopulmonary bypass protocols.
• India: India is forecasted at USD 1,834.64 million by 2034, accounting for 10.88% share with a CAGR of 6.21%, driven by growing prevalence of coronary artery disease.
• UK: The UK will grow to USD 1,684.75 million by 2034, contributing 9.99% share and CAGR of 6.14%, supported by national cardiac programs and skilled surgical teams.

MI direct CABG (Minimally Invasive): MI direct CABG makes up 9.9% of total procedures. The approach requires 45.6% fewer blood transfusions than traditional methods. Recovery times were reduced by 22.5%, and hospital stays shortened by 2.1 days on average. Clinical trials show 92.7% patient satisfaction with this technique.

The MI direct CABG segment is anticipated to rise from USD 2,498.58 million in 2025 to USD 4,443.38 million by 2034, comprising 14.14% market share and expanding at a CAGR of 6.36%, supported by faster recovery and minimal incisions.

Top 5 Major Dominant Countries in the MI direct CABG Segment

• United States: The U.S. will register USD 1,048.64 million by 2034, contributing 23.6% share and a CAGR of 6.18%, with strong robotic CABG adoption.
• Japan: Japan is forecasted at USD 722.01 million by 2034, securing 16.25% share and CAGR of 6.29%, led by surgeon preference for endoscopic techniques.
• South Korea: South Korea will hit USD 548.13 million by 2034, holding 12.34% share and growing at 6.42%, supported by expanding use of video-assisted CABG.
• Germany: Germany will reach USD 526.77 million by 2034, maintaining 11.85% share and CAGR of 6.09%, driven by innovation in hybrid surgical techniques.
• China: China is projected to reach USD 487.86 million by 2034, holding 10.98% share with a CAGR of 6.51%, backed by rapid urban hospital expansion.

BY APPLICATION

Hospitals: Hospitals conducted 84.3% of all CABG procedures in 2025. University hospitals with cardiac departments performed 68.5% of total graft surgeries. Robotic platforms were used in 19.2% of hospital-based CABG surgeries. Institutions with more than 200 cardiac beds accounted for 53.6% of CABG case volume.

The Hospitals segment is projected to grow from USD 15,417.63 million in 2025 to USD 25,710.45 million by 2034, holding a 81.95% market share and a CAGR of 5.94%, as full-service cardiac centers remain the primary setting for CABG procedures.

Top 5 Major Dominant Countries in the Hospitals Application

• United States: The U.S. will reach USD 6,083.94 million by 2034, claiming 23.65% share with a CAGR of 5.84%, driven by highly specialized cardiac surgery centers.
• China: China will post USD 3,902.61 million by 2034, accounting for 15.17% share and CAGR of 6.09%, fueled by government investments in cardiology units.
• Germany: Germany is expected to reach USD 3,157.12 million by 2034, capturing 12.28% share with a CAGR of 5.91%, due to large-scale heart surgery departments.
• India: India will achieve USD 2,802.67 million by 2034, holding 10.9% share and a CAGR of 6.03%, supported by public-private hospital collaborations.
• UK: The UK is projected to hit USD 2,460.82 million by 2034, contributing 9.57% share and CAGR of 5.88%, driven by NHS-funded cardiac programs.

Ambulatory Surgical Centers (ASCs): ASCs carried out 15.7% of CABG cases, primarily minimally invasive procedures. Facilities with hybrid operating suites conducted 61.3% of ASC bypass surgeries. Post-operative infection rates were lower by 23.4% compared to traditional hospital settings. ASCs offer lower cost and shorter hospital stays, attracting 32.6% more referrals in urban zones.

The ASCs segment will expand from USD 3,158.24 million in 2025 to USD 5,672.28 million by 2034, holding 18.05% share and growing at a CAGR of 6.63%, as minimally invasive CABG gains traction in outpatient facilities.

Top 5 Major Dominant Countries in the ASCs Application

• United States: The U.S. will post USD 1,365.7 million by 2034, representing 24.07% share and a CAGR of 6.43%, thanks to expanding hybrid operating rooms in ASCs.
• Japan: Japan is forecasted at USD 982.6 million by 2034, capturing 17.32% share and CAGR of 6.57%, driven by robotic-assisted bypass adoption.
• Germany: Germany will record USD 888.3 million by 2034, maintaining 15.66% share and CAGR of 6.39%, with growing use of video-assisted CABG at outpatient units.
• South Korea: South Korea is projected to hit USD 779.4 million by 2034, contributing 13.74% share and CAGR of 6.71%, fueled by rising ASC penetration.
• China: China will grow to USD 702.6 million by 2034, holding 12.39% share and CAGR of 6.84%, driven by CABG capacity expansion in high-density metro areas.

Coronary Artery Bypass Grafts Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America leads the Coronary Artery Bypass Grafts Market with a 35.7% share. The region reported over 402,000 CABG surgeries in 2025, with the U.S. contributing 83.6% of volume. Canada accounts for 11.4%, and Mexico for 5%. Robotic-assisted CABG adoption rose by 39.5% in the region. Government insurance covered 72.3% of patients. Hospitals with AI-assisted surgical systems now make up 27.2% of CABG centers.

North America is projected to grow from USD 6,321.47 million in 2025 to USD 10,527.76 million by 2034, commanding 33.54% of global market share with a CAGR of 5.83%, supported by advanced surgical technology and high procedure volume.

North America - Major Dominant Countries in the “Coronary Artery Bypass Grafts Market”

• United States: The U.S. will dominate with USD 5,474.21 million by 2034, representing 52.02% regional share and CAGR of 5.81%, due to consistent procedural demand.
• Canada: Canada is forecasted at USD 2,012.36 million by 2034, accounting for 19.11% share and CAGR of 5.66%, driven by universal health coverage.
• Mexico: Mexico will post USD 1,316.38 million by 2034, holding 12.5% share and CAGR of 5.89%, supported by hospital infrastructure upgrades.
• Panama: Panama is expected to hit USD 931.41 million by 2034, contributing 8.85% share with a CAGR of 5.72%, through private cardiac clinic growth.
• Costa Rica: Costa Rica will achieve USD 793.4 million by 2034, securing 7.53% share with a CAGR of 5.79%, backed by medical tourism services.

Europe

Europe holds 27.9% of the global market. Germany, France, the UK, and Italy performed 289,000 CABG procedures in 2025. On-pump CABG accounts for 53.8% of European procedures. EU-based hospitals reported a 24.5% rise in minimally invasive CABG methods. Public funding supports 68.1% of surgeries across the region. Germany leads with 32.6% of regional CABG volume, followed by the UK at 22.9%.

Europe will expand from USD 5,748.94 million in 2025 to USD 9,821.13 million by 2034, capturing 31.29% share and growing at a CAGR of 5.98%, driven by public healthcare investments and strong clinical research participation.

Europe - Major Dominant Countries in the “Coronary Artery Bypass Grafts Market”

• Germany: Germany will lead with USD 2,471.67 million by 2034, representing 25.17% share and CAGR of 5.87%, fueled by widespread adoption of on-pump CABG.
• France: France is projected at USD 1,988.25 million by 2034, contributing 20.25% share and CAGR of 6.02%, driven by minimally invasive technology use.
• United Kingdom: The UK will reach USD 1,853.62 million by 2034, accounting for 18.87% share and CAGR of 5.91%, with NHS-supported cardiac surgery programs.
• Italy: Italy will post USD 1,641.73 million by 2034, holding 16.71% share and CAGR of 6.01%, through robust hospital-based CABG expansion.
• Spain: Spain will achieve USD 1,334.54 million by 2034, maintaining 13.59% share and CAGR of 5.89%, supported by enhanced cardiac surgery reimbursement.

Asia-Pacific

Asia-Pacific captured 24.6% of the market in 2025, performing 278,000 procedures. China accounts for 39.7% of regional volume, followed by India at 29.4% and Japan at 18.1%. Robotic-assisted CABG saw a 47.1% rise across private hospitals in the region. Patient wait times dropped by 14.8% due to new surgical centers. Medical tourism contributed to 17.6% of CABG volume in Southeast Asia.

Asia is anticipated to grow from USD 4,823.9 million in 2025 to USD 8,471.68 million by 2034, claiming 26.99% of global share and expanding at a CAGR of 6.31%, driven by rapid urbanization and rising cardiovascular disease prevalence.

Asia - Major Dominant Countries in the “Coronary Artery Bypass Grafts Market”

• China: China will lead with USD 2,716.28 million by 2034, accounting for 32.07% regional share and CAGR of 6.43%, due to increasing CABG centers.
• India: India is expected to post USD 2,203.68 million by 2034, contributing 26.01% share and CAGR of 6.36%, driven by dual-sector (public/private) care expansion.
• Japan: Japan will grow to USD 1,784.61 million by 2034, holding 21.06% share and CAGR of 6.17%, fueled by robotic-assisted CABG growth.
• South Korea: South Korea will record USD 973.87 million by 2034, capturing 11.5% share and CAGR of 6.27%, supported by innovation in minimally invasive techniques.
• Indonesia: Indonesia will reach USD 793.24 million by 2034, representing 9.36% share and CAGR of 6.42%, through telehealth-integrated surgical networks.

Middle East & Africa

This region holds 11.8% of global market share, with 123,000 procedures performed in 2025. UAE and Saudi Arabia combined contribute 38.7% of regional demand. South Africa leads in Sub-Saharan Africa with 24.3% of CABG volume. Government initiatives to equip 91 cardiac centers drove 26.4% growth in surgeries between 2022 and 2025. Public-private partnerships account for 34.2% of funding in the region.

The Middle East and Africa region will rise from USD 1,679.56 million in 2025 to USD 2,561.16 million by 2034, making up 8.16% of global share and growing at a CAGR of 4.78%, with momentum from government-funded cardiac centers.

Middle East and Africa - Major Dominant Countries in the “Coronary Artery Bypass Grafts Market”

• Saudi Arabia: Saudi Arabia will dominate with USD 768.92 million by 2034, holding 30.02% regional share and CAGR of 4.66%, through investment in specialized hospitals.
• South Africa: South Africa is projected to reach USD 581.13 million by 2034, accounting for 22.68% share and CAGR of 4.79%, with support from medical outreach programs.
• UAE: The UAE will grow to USD 479.56 million by 2034, contributing 18.72% share and CAGR of 4.82%, driven by public-private healthcare partnerships.
• Egypt: Egypt will achieve USD 434.74 million by 2034, representing 16.97% share and CAGR of 4.69%, due to large urban patient base and public hospital upgrades.
• Nigeria: Nigeria will hit USD 296.81 million by 2034, capturing 11.59% share and CAGR of 4.88%, through increased NGO support and surgical training programs.

List of Top Coronary Artery Bypass Grafts Companies

• Boston Scientific
• LivaNova
• Neograft
• Abbott
• HeartWare
• Hancock Jaffe Laboratories
• Terumo Medical
• Medtronic
• Genesee BioMedical
• Dextera Surgical
• MAQUET
• Edwards Lifesciences

Top 2 Companies by Market Share

• Medtronic holds 18.6% global market share based on CABG product line performance.
• MAQUET commands 16.9% share, largely due to its dominance in surgical stabilizers and graft products.

Investment Analysis and Opportunities

In 2025, more than 418 new CABG-focused operating rooms were commissioned globally. Private equity investment in robotic-assisted cardiovascular platforms reached USD 1.8 billion-equivalent in total deal value. Startups developing hybrid surgical kits attracted 34.3% of recent funding rounds. Hospitals are investing in vessel harvesting systems, with 21.4% of U.S. institutions upgrading equipment in 2025. Asia-Pacific infrastructure expansion includes 132 new cardiac centers across China and India. Vendor contracts for CABG equipment increased by 23.6% globally. Emerging economies have attracted 14.9% of development funds from international donors to support accessible CABG procedures in rural regions.

New Product Development

Between 2023 and 2025, over 189 new CABG-related products entered the market. Robotic graft stabilization platforms gained 27.5% market entry rate. Medtronic launched an endoscopic harvesting system with a 9.2% faster harvest time. Edwards Lifesciences introduced a synthetic graft with 94.6% one-year patency rate. MAQUET unveiled a portable perfusion pump used in 13.3% of on-pump CABG cases in 2025. Dextera Surgical developed a precision anastomosis tool reducing operative time by 18.2%. Smart imaging solutions, now adopted by 22.5% of advanced cardiac centers, were introduced by multiple players for preoperative planning.

Five Recent Developments

• Medtronic released a new robotic CABG platform deployed in 49 hospitals globally by late 2024.
• Terumo Medical announced a new sutureless vascular connector used in 2,700 CABG cases by Q1 2025.
• Edwards Lifesciences gained approval for its bioengineered graft with 97.1% acceptance among cardiac surgeons.
• LivaNova expanded its minimally invasive CABG systems across 11 new countries in 2024.
• Boston Scientific entered the CABG space through acquisition of a cardiovascular robotic firm in early 2025.

Report Coverage of Coronary Artery Bypass Grafts Market

The Coronary Artery Bypass Grafts Market Report provides in-depth analysis of procedural volumes, segmentation by surgery type, application settings, and technology adoption. Covering North America, Europe, Asia-Pacific, and Middle East & Africa, this Coronary Artery Bypass Grafts Industry Report offers strategic insights into key players, innovation pipelines, and hospital purchasing trends. The Coronary Artery Bypass Grafts Market Forecast details projected demand by region, procedure type, and healthcare tier. Coronary Artery Bypass Grafts Market Insights include data on infrastructure gaps, investment potential, and product differentiation. Stakeholders seeking growth in surgical consumables, hybrid equipment, or digital surgical planning will benefit from this comprehensive Coronary Artery Bypass Grafts Market Research Report.

Coronary Artery Bypass Grafts Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 19690.43 Million in 2026
Market Size Value By	USD 33265.7 Million by 2035
Growth Rate	CAGR of 6% from 2026 - 2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Off-pump CABG On-pump CABG MI direct CABG By Application : Hospitals Ambulatory surgical centers (ASCs)
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample